These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27237765)

  • 1. Pancolitis a novel early complication of Alemtuzumab for MS treatment.
    Vijiaratnam N; Rath L; Xu SS; Skibina O
    Mult Scler Relat Disord; 2016 May; 7():83-4. PubMed ID: 27237765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    Blasco MR; Ramos A; Malo CG; García-Merino A
    J Neurol; 2017 Jan; 264(1):168-169. PubMed ID: 27888417
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
    Perumal JS; Foo F; Cook P; Khan O
    Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
    Hartung HP; Aktas O; Boyko AN
    Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

  • 11. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update on Current Care Guideline: Multiple sclerosis].
    Remes A; Airas L; Atula S; Färkkilä M; Hartikainen P; Koivisto K; Mäenpää E; Ruutiainen J; Sumelahti ML;
    Duodecim; 2015; 131(5):500-1. PubMed ID: 26237913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in multiple sclerosis: an update.
    Gross RH; Krieger S
    Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Drug For Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
    [No Abstract]   [Full Text] [Related]  

  • 15. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F; Porchet H; Glanzman R; Schneble HM; Vidal V; Audoli-Inthavong ML; Lambert E; Hartung HP
    Mult Scler Relat Disord; 2016 Sep; 9():95-100. PubMed ID: 27645352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
    Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
    Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of meningitis associated with ocrelizumab therapy.
    Theriault M; Solomon AJ
    Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
    Jones DE; Goldman MD
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1281-91. PubMed ID: 25148422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Sheikh-Taha M; Corman LC
    Mult Scler; 2017 May; 23(6):872-874. PubMed ID: 28290754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.